The Major Depressive Disorder drug treatment market is expanding rapidly due to the increasing demand for antidepressants and the disease’s profound impact on quality of life. In 2023, the major depressive disorder market across the 7MM was valued at an impressive USD 7.2 billion, and it’s poised for even greater expansion, with exciting growth on the horizon through 2034. The major depressive disorder treatment landscape has seen significant advancements, with multiple approved therapies playing a crucial role in symptom management. Currently, widely prescribed drugs for MDD include AbbVie and Gedeon Richter’s VRAYLAR, Axsome Therapeutics’ AUVELITY, Johnson & Joh...
